Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928.[A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.[A262601] Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the need for therapeutic monitoring, and serious side effects of secondary cancer and birth defects.[A262606]
Synonyms
Carbamohydroxamic acid
Hydroxycarbamide
Hydroxycarbamid
Hidroxicarbamida
N-Carbamoylhydroxylamine
Hydrea
N-Hydroxyurea
Carbamohydroximic acid
Hydroxyurea
Oxyurea
Hydroxycarbamidum
Carbamoyl oxime
Hydroxyharnstoff
Carbamyl hydroxamate
Brand Names
Mylan-hydroxyurea
Apo-hydroxyurea
Droxia
Siklos
Hydroxyurea
Xromi
Riva-hydroxyurea
Hydrea
Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.[L41150]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
